Arrowhead (ARWR) Q2 2026 Earnings Transcript

Arrowhead reported >400 REDEMPLO prescriptions since launch, with U.S. prescription growth nearly tripling during the quarter and accelerating >40% in the last 4 weeks; first full-quarter U.S. net sales were about $1 million. Management also highlighted $1.8 billion in cash and investments, a $700 million convertible note sale plus $230 million of stock, and a $25 million upfront / up to $975 million milestone license deal with Madrigal for ARO-PNPLA3. Key catalysts remain Q3 readouts for SHASTA-3/-4 and ARO-DIMER-PA, with ARO-MAPT data expected in late Q3 or early Q4.

Analysis

ARWR is transitioning from a single-asset launch story into a multi-catalyst platform rerating, and that matters more than the near-term revenue print. The key second-order effect is that REDEMPLO’s pricing reset looks less like defensive price competition and more like portfolio architecture: a unified FCS/SHTG price gives them a cleaner payer narrative ahead of a much larger addressable market, while the international approvals broaden optionality without forcing the U.S. commercial org to absorb all growth alone.

The real inflection point is Q3/Q4 data density. If SHASTA-3/-4 show even modest apnea-leaning? No — the market will care about whether triglyceride efficacy translates into a credible pancreatitis signal using the modified endpoint framework. A clean readout would do three things at once: validate label expansion, reduce the chance that REDEMPLO remains boxed into a rare-disease niche, and justify continued premium pricing despite a more competitive APOC3 landscape. Conversely, any ambiguity on pancreatitis or tolerability would disproportionately compress the multiple because the street is already capitalizing a large part of the SHTG opportunity.

The pipeline breadth is real, but the market will likely treat it as two distinct baskets: de-risked cardiometabolic assets and longer-dated venture-style CNS/obesity shots on goal. ARO-DIMER-PA is the highest convexity science readout because it could create a new modality category, but it is also the most brittle if early biomarker effects disappoint. The Madrigal deal is strategically rational capital recycling; it signals management is willing to monetize non-core optionality, which should support the bullish thesis on capital discipline rather than dilution fear.

Bottom line: consensus may be underestimating how much the next six months can re-rate ARWR if SHASTA and DIMER both work, but it may also be overestimating how cleanly the current launch scales into SHTG. This is a catalyst-rich name where execution quality, not just biology, will determine whether the stock graduates from story stock to durable platform compounder.

Key Decisions for Investors

• Long ARWR into Q3 catalysts with a 2-4 month horizon; best risk/reward is ahead of SHASTA-3/-4 and ARO-DIMER-PA readouts, with upside if both validate the platform and downside capped by the strong balance sheet.
• Buy ARWR Jan-2027 calls or call spreads to express event convexity; use defined risk because binary data in Q3/Q4 can re-rate the stock sharply in either direction.
• Pair trade: long ARWR / short MDGL on a 3-6 month horizon if you want to express platform optionality versus a more concentrated NASH commercial story; ARWR has multiple shots on goal and better catalyst density.
• If holding ARWR outright, trim on a failed SHASTA pancreatitis signal or vague DIMER biomarker data; those are the two most likely catalysts to compress the multiple by 25-40% in the following sessions.
• Watch for weakness in ARWR after the data readout if the stock has run into the events; that would be the higher-quality entry for a 12-month position because commercialization and ex-U.S. launches reduce fundamental downside.